Pharmacodynamic effect of mTOR inhibition-based immunosuppressive therapy on dendritic cell and natural killer cell subsets after renal transplantation
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxaf026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Sabine Weber und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology and Hepatology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-Univer…. Hauptthemen laut MEDLINE: Dendritic Cells, Kidney Transplantation, Killer Cells, Natural, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Robert-Pfleger Stiftung, Bamberg, Germany, German Research Foundation, Chinese Scholarship Council.
Abstract (Originalsprache)
Background mTOR inhibitor therapy is solely monitored via pharmacokinetics after kidney transplantation, which may not accurately reflect the effectiveness of PI3K-Akt-mTOR pathway blockade, potentially leading to inadequate or excessive immunosuppression. The pharmacodynamic effect of mTOR inhibition on natural killer (NK) cells and dendritic cell (DC) subsets after renal transplantation has not been investigated so far. Methods Phosphoflow cytometry was employed in this cross-sectional study to evaluate the extent of mTOR inhibition in peripheral DC and NK cell subsets by assessing p70S6 kinase phosphorylation in kidney transplant recipients treated with mTOR inhibitors either in combination with calcineurin inhibitors (mTORi + CNI, n = 17) or mycophenolate sodium (mTORi + MPA, n = 9). The control group comprised nine end-stage renal disease patients undergoing dialysis therapy and 17 healthy volunteers. Results mTOR inhibitor-based therapy significantly reduced p70S6K phosphorylation levels in CD3−CD56+ NK cells compared to healthy controls, while p70S6K phosphorylation among HLA-DR+ Lin− total DCs was not different. In comparison to mTORi + MPA therapy, renal transplant patients receiving mTORi + CNI treatment exhibited a stronger inhibition of p70S6K phosphorylation in HLA-DR+ Lin− total DCs, CD123+CD11c− plasmacytoid DCs, CD123−CD11c+ myeloid DCs, and CD16−CD56bright NK cells. However, the serum trough levels of mTORi showed no correlation with p70S6K phosphorylation levels in all investigated cell subsets. Conclusion mTORi selectively suppressed p70S6K phosphorylation in specific DC and NK subtypes. Evaluating p70S6K phosphorylation through phosphoflow cytometry might serve as a clinically applicable method to comprehend immune cell subset-specific effects of mTOR inhibition, providing detailed pharmacodynamic insights for tailoring mTORi therapy on an individual basis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Gastroenterology and Hepatology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
- Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
- Institute of Immunology, Friedrich-Schiller-University Jena, Jena University Hospital, Jena, Germany.
- Laboratory of Dendritic Cell Biology, Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
- FAU Profile Center Immunomedicine (FAU I-MED), Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
ORCID-Profile: Xinyi Wei, André Hoerning
Förderung
- Robert-Pfleger Stiftung, Bamberg, Germany
- German Research Foundation
- Chinese Scholarship Council
Zitieren
APA
Weber, S., Wei, X., Chen, G., Yankouskaya, K., Yin, D., Allabauer, I., Jobst-Schwan, T., Wiesener, M., Schiffer, M., Dudziak, D., Lehmann, C. H. K., Woelfle, J., & Hoerning, A. (2025). Pharmacodynamic effect of mTOR inhibition-based immunosuppressive therapy on dendritic cell and natural killer cell subsets after renal transplantation. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxaf026
Vancouver
Weber S, Wei X, Chen G, Yankouskaya K, Yin D, Allabauer I, et al. Pharmacodynamic effect of mTOR inhibition-based immunosuppressive therapy on dendritic cell and natural killer cell subsets after renal transplantation. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxaf026
BibTeX
@article{Weber2025,
author = {Weber, Sabine and Wei, Xinyi and Chen, Guixia and Yankouskaya, Katharina and Yin, Decheng and Allabauer, Ida and Jobst-Schwan, Tilman and Wiesener, Michael and Schiffer, Mario and Dudziak, Diana and Lehmann, Christian H K and Woelfle, Joachim and Hoerning, André},
title = {Pharmacodynamic effect of mTOR inhibition-based immunosuppressive therapy on dendritic cell and natural killer cell subsets after renal transplantation},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxaf026}
}
EUVIMED